Statements (30)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:chemical_compound
gptkb:drug |
| gptkbp:administeredBy |
oral tablet
|
| gptkbp:approvalYear |
2022
|
| gptkbp:approvedBy |
gptkb:FDA
|
| gptkbp:ATCCode |
L01XX81
|
| gptkbp:brand |
Rezlidhia
|
| gptkbp:CASNumber |
1374639-75-4
|
| gptkbp:developer |
Forma Therapeutics
|
| gptkbp:hasMolecularFormula |
C15H14ClFN6O
|
| gptkbp:hasSMILES |
C1=CC(=C(C=C1N2C=NC3=C2N=CN=C3Cl)F)C(=O)NC4=CC=CC=N4
|
| https://www.w3.org/2000/01/rdf-schema#label |
olutasidenib
|
| gptkbp:indication |
relapsed or refractory acute myeloid leukemia with susceptible IDH1 mutation
|
| gptkbp:KEGGID |
D12345
|
| gptkbp:legalStatus |
prescription only
|
| gptkbp:mechanismOfAction |
IDH1 inhibitor
|
| gptkbp:PubChem_CID |
CHEMBL4297596
71244453 |
| gptkbp:routeOfAdministration |
oral
|
| gptkbp:sideEffect |
nausea
fatigue arthralgia leukocytosis differentiation syndrome increased liver enzymes |
| gptkbp:target |
IDH1 mutant protein
|
| gptkbp:UNII |
6Q6X5Q7B8N
|
| gptkbp:usedFor |
treatment of acute myeloid leukemia
|
| gptkbp:bfsParent |
gptkb:L01XE29
|
| gptkbp:bfsLayer |
6
|